Maxalt Migräne

Rizatriptan, the active ingredient in Maxalt Migräne, is a Triptan (5‑HT1B/1D receptor agonist) presented as an oral tablet for oral use. It is indicated for the acute treatment of migraine attacks in adults.

GNH USA supplies Maxalt Migräne as a licensed, GDP‑compliant international pharmaceutical supplier, providing the product to hospitals, pharmacies, and clinics worldwide with adherence to stringent quality standards and regulatory requirements. The company’s global logistics network ensures timely delivery and proper handling of the medication across diverse markets.

Rizatriptan belongs to the triptan class and is used to treat acute migraine episodes.

Migraine without aura: rapid relief of headache and associated symptoms. Migraine with aura: aborts the attack and may lessen aura severity. Migraine-associated nausea: helps reduce nausea accompanying the headache.

Rizatriptan may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Chest tightness or pressure. - Tingling or numbness in the fingers or face. - Dizziness or light‑headedness. - Fatigue or drowsiness. - Nausea or abdominal discomfort. - Dry mouth.

Serious or Rare Side Effects: - Coronary vasospasm or myocardial ischemia. - Serotonin syndrome, especially with other serotonergic agents. - Severe allergic reactions (anaphylaxis, angioedema). - Hypertension or sudden increase in blood pressure. - Cardiac arrhythmias. - Persistent visual disturbances.

Before using Rizatriptan, consider the following safety measures.

Cardiovascular assessment: evaluate history of heart disease or ischemic events. Serotonergic co‑medication: avoid concurrent use of SSRIs, SNRIs, MAO inhibitors, or other triptans. Pregnancy and lactation: use only if potential benefit justifies potential risk. Renal or hepatic impairment: dose adjustment may be required based on clinical judgment. Age restrictions: not established for use in children or adolescents. Store at ambient temperature: keep in the original packaging, protect from moisture and direct sunlight.

Rizatriptan can interact with several drug classes; awareness helps prevent adverse outcomes.

Major Interactions (Avoid): - MAO inhibitors: risk of severe hypertension. - Other triptans or ergot alkaloids: additive vasoconstriction. - SSRIs, SNRIs, or other serotonergic agents: potential serotonin syndrome. - Strong CYP3A4 inhibitors (e.g., ketoconazole): increased plasma levels.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., erythromycin): may raise rizatriptan exposure. - Antihypertensive agents: monitor blood pressure changes. - Oral contraceptives: possible alteration of efficacy. - NSAIDs: increased risk of cardiovascular side effects.